Nancy Patterson

University of California at Los Angeles, CA, December 1, 2010, Business of Science Title: Successful Commercialization of Emerging LifeScience Technologies Los Angeles, CA

IESE Business School, University of Navarra, November 3, 2010 Title: Entrepreneurship and Innovation in Life Science Technology in 2020Global Meeting of the Health-Care Industry, The Health-care Industry in 2020, Barcelona Spain

Caltech (California Institute of Technology), May 26, 2010, The Biotech Club Industry Night, Keynote Speech, Biotechnology: Title: The Direction of Investments in Biotechnology Innovation.Pasadena, CA

University of California at Los Angeles, CA, April 28, 2010, Business of Science, Title: Successful Commercialization of Emerging LifeScience Technologies Los Angeles, CA

JointVentures, November 9, 2010, Moderator, Title: Healthcare Reform and its Impact on Ortho/Spine, Grant Hyatt, San Francisco, CA

Webinar: Elsevier Medtech Insight IN3 Webinar Series, December 11, 2009, Title: Avoiding the 14 Biggest Mistakes Made By Emerging Lifescience Companies

Elsevier Medtech Insight Medical Device Investor Forum / IN3 East, Westin Copley Plaza, Boston, MA, June 23, 2009, Title: Setting the Right Trajectory: Avoiding the 14 Biggest Mistakes Made By Emerging Lifescience Companies

University of California at Los Angeles, CA, April 9, 2009, Business of Science, Title: Hot Emerging Biomedical Technologies and Their Successful Commercialization, Los Angeles, CA

Stanford University, Management Science and Engineering 256, May 22, 2009, Title: Early Stage Technology Assessment

Hospital Clínic de Barcelona (Dr. Joan Bigorra and LIM Global), December 9, 2008, Title: What’s Hot and What’s Not in Biomedical Technology, Barcelona, Spain

Technion University, December 4, 2008, Title: Exit Strategies for Lifescience Technologies: Determining the Path to Obtain Maximum Value, Haifa, Israel

Biomedical Engineering Society, AIMBE invited presenter, October 3, 2008, Title: AIMBE Public Policy session - Translational BME, St. Louis, MO

University of California at Los Angeles, October. 30, 2008, Business of Science, Title: Presenting Your Compelling Lifescience Technology, Los Angeles, CA,

University of California at Los Angeles, May 30, 2008, Business of Science, Title: Developing a Business Plan for Increased Valuation, Los Angeles, CA

University of California at San Diego, January 14, 2008, Biomedical Engineering, Title: Presenting Your Lifescience Technology: Template for Success, San Diego, CA

Invited presenter, Licensing Executives Society, November 2007, Title: Emerging Biomedical Technologies: Landscape for Successful Technology Selection, Los Angeles, CA

Keynote Speaker, National Academies Round Table, July 17, 2007, Biomedical Engineering Materials and Applications, Title: Surgical Sealants and Tissue Adhesives, Woods Hole, MA

California Institute of Technology, May 2, 2007, Title: Emerging Life Science Technology: From Concept to Reality, Pasadena, California

Invited Speaker, Licensing Executives Society Annual Meeting, February 21, 2007, Title: Emerging Biomedical Technology: What’s Hot and What’s NOT, San Francisco, CA

Stanford University, Kauffman Global Scholars, February 22, 2007, Title: Emerging Lifescience Technology and Successful Commercialization, Palo Alto, CA

University of Washington, Biomedical Engineering, January 20, 2007, Title: Presenting Your Lifescience Technology: Template for Success, Seattle, WA

Keynote speaker, BME Idea, Biomedical Engineering Society Annual Conference, October 11, 2006, Chicago, IL, Title: “Concepts for Commercialization”;

Nancy Patterson, "Emerging Biomedical Technologies: What's Hot and What's Not", Los Angeles Chapter of Licensing Executive Society, March 23, 2006

Invited presenter, Licensing Executives Society, February 19, 2006, Title: Emerging Biomedical Technologies: Landscape for Successful Technology Selection, Irvine, CA

Nancy Patterson, "Hot Emerging Biomedical Technologies and Their Successful Commercialization", Buena Ventura Chapter of IEEE Engineering and Medicine in Biology Society, March 30, 2005

Course developer and Key Presenter, University of California at Irvine, January 13, 2005 - January 27, 2005, Title: Securing Venture Capital Funding for Your Medical Device, Irvine, CA

Nancy Patterson, "Securing Venture Capital Funding for your Medical Device", University of California, Irvine, 2005

Nancy Patterson, "Securing Venture Capital Funding for your Medical Device", University of California, Irvine, 2004

Elise (Dick) Wolf

Vorp, D.A., Gorcsan, J., Mandarino, W.A., Dick, Elise K., Steed, D.L., Webster, M.W. Noninvasive estimation of the biomechanical properties of the aneurysmal and non-aneurysmal abdominal aorta. Presented at the Association for Academic Surgery Meeting in Albuquerque, New Mexico, November 1994.

Norma Vela Roch

ABSTRACTS (*oral presentation)
Kong L, Vela-Roch N, Talal N, Dang H. Bcl-2 and Bcl-xl inhibit Fas-mediated apoptosis of salivary epithelial cells. Arth. & Rheum. 41:S354, 1998.

*Vela-Roch N, Kong L, Talal N, Dang H. Sulphasalazine and its metabolites may mediate their therapeutic effects through apoptosis. Arth. & Rheum. 41:S160, 1998.

Sakata K-M, Sakata A, Kong L, Vela-Roch N, Talal N, Dang H. Monocytes rescue T cells from apoptosis is CD40/CD40L-dependent and not impaired in patients with Systemic Lupus Erythematosus. Arth. & Rheum. 41:S42, 1998.

Sakata K-M, Sakata A, Dang H, Vela-Roch N, Ecalante A, Kong L, Nakabayashi T, Cheng J, Talal N. Fas (CD95)-transduced signal preferentially stimulates lupus peripheral T lymphocytes activation. Arth. & Rheum. 39:S141, 1996.

Flescher E, Dang H, Vela-Roch N, Ogawa N, Talal N. Defective binding to specific enhancer sequences in primary but not secondary Sjogren’s syndrome (SS). Arth. & Rheum. 37:S285, 1994.

Flescher E, Vela-Roch N, Escalante A, Talal N. The Oct-1 transcription factor abnormality in Sjogren’s syndrome (SS) is correctable by dephosphorylation and does not occur in systemic lupus erythematosus (SLE). Arth. & Rheum. 36:S43, 1993.

Flescher E, Vela-Roch N, Talal N. Decreased expression of the Oct-1 transcription factor regulating the T cell interleukin-2 (IL-2) gene in Sjogren’s syndrome. Arth. & Rheum. 35:S61, 1992.